This trial employing MGBG, vinblastine, and cisplatin in patients with advanced NSCLC produced a 10% response rate with no durable responses. This is disappointing compared to previously cited studies, although the median overall survival of 7.0 months is comparable. The relatively mild toxicity noted in this trial suggests that more aggressive use of the same combination may be feasible.
|Original language||English (US)|
|Number of pages||2|
|Journal||Investigational New Drugs|
|State||Published - Feb 1993|
ASJC Scopus subject areas
- Pharmacology (medical)